Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
Gass P, Thiel FC, Häberle L, Ackermann S, Theuser AK, Hummel N, Boehm S, Kimmig R, Reinthaller A, Becker S, Hilpert F, Janni W, Vergote I, Harter P, Emons J, Hein A, Beckmann MW, Fasching PA, Pöschke P; AGO Uterus Commission. Gass P, et al. Among authors: thiel fc. Gynecol Oncol. 2024 Apr;183:25-32. doi: 10.1016/j.ygyno.2024.03.002. Epub 2024 Mar 14. Gynecol Oncol. 2024. PMID: 38490057 Free article. Clinical Trial.
Topotecan in cervical cancer.
Ackermann S, Beckmann MW, Thiel F, Bogenrieder T. Ackermann S, et al. Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1215-23. doi: 10.1111/j.1525-1438.2007.01003.x. Int J Gynecol Cancer. 2007. PMID: 17997795 Review.
Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.
Polterauer S, Schwameis R, Grimm C, Hillemanns P, Jückstock J, Hilpert F, de Gregorio N, Hasenburg A, Sehouli J, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Harter P, Wimberger P, Kölbl H, Reinthaller A, Woelber L, Mahner S. Polterauer S, et al. Gynecol Oncol. 2019 May;153(2):286-291. doi: 10.1016/j.ygyno.2019.02.007. Epub 2019 Feb 11. Gynecol Oncol. 2019. PMID: 30760408
Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F. Emons G, et al. Gynecol Oncol. 2016 Mar;140(3):450-6. doi: 10.1016/j.ygyno.2015.12.025. Epub 2015 Dec 28. Gynecol Oncol. 2016. PMID: 26731724 Clinical Trial.
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Pfisterer J, et al. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305099 Free article. Clinical Trial.
Patterns and Trends of Herbal Medicine Use among Patients with Gynecologic Cancer.
Theuser AK, Hack CC, Fasching PA, Antoniadis S, Grasruck K, Wasner S, Knoll S, Sievers H, Beckmann MW, Thiel FC. Theuser AK, et al. Among authors: thiel fc. Geburtshilfe Frauenheilkd. 2021 Jun;81(6):699-707. doi: 10.1055/a-1487-6284. Epub 2021 Jun 21. Geburtshilfe Frauenheilkd. 2021. PMID: 34168382 Free PMC article.
Hormone replacement therapy and prognosis in ovarian cancer patients.
Hein A, Thiel FC, Bayer CM, Fasching PA, Häberle L, Lux MP, Renner SP, Jud SM, Schrauder MG, Müller A, Wachter D, Strehl J, Hartmann A, Beckmann MW, Rauh C. Hein A, et al. Among authors: thiel fc. Eur J Cancer Prev. 2013 Jan;22(1):52-8. doi: 10.1097/CEJ.0b013e328355ec22. Eur J Cancer Prev. 2013. PMID: 22694828
68 results